Jefferies Raises Acadia Pharmaceuticals (ACAD) PT to $18 on Pimavanserin Win
Tweet Send to a Friend
Jefferies boosted its price target on Acadia Pharmaceuticals (NASDAQ: ACAD) from $13 to $18 after the company announced Thursday that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
